News summaryFierce PharmaNov 12, 2026, 12:00 PM
China approves Lilly’s oral obesity drug orforglipron
regulatory_actionpharmaceuticals
Fierce Pharma reported Nov. 12 that China approved Eli Lilly’s oral GLP-1 orforglipron for weight loss, the first oral GLP-1 approval for weight management in China. Lilly’s separate orforglipron application for type 2 diabetes remained under NMPA review.